High-density lipoprotein (HDL) is a strong antioxidant, anti-inflammatory, and antisenescence molecule. However, in the current study, HDL from the elderly group (E-HDL) exhibited increased glycation with apolipoprotein (apo) A-I multimerization and decreased phospholipid content. Similarly, glycated apoA-I (gA-I) by fructosylation has a covalently multimerized band without a crosslinker and impaired phospholipid-binding ability. Treatment of human dermal fibroblasts and macrophages with E-HDL and gA-I caused more severe cellular senescence and foam cell formation, respectively; however, treatment with HDL from a young group (Y-HDL) and native apoA-I (nA-I) suppressed senescence and atherosclerosis. E-HDL 3 and reconstituted HDL (rHDL) containing gA-I showed enhanced cholesterol influx into macrophages compared with Y-HDL 3 and nA-I-rHDL. In conclusion, E-HDL and gA-I-rHDL share similar physiologic properties in macrophages and human dermal fibroblasts. E-HDL and gA-I-rHDL exacerbated cellular senescence and atherosclerosis with increased cellular cholesterol influx.
H IGH-DENSITY lipoproteins (HDLs) are strong antioxidant and anti-inflammatory molecules in the serum (1) . Inflammation is a fundamental cause of almost all chronic metabolic disorders and plays a major role in cardiovascular disease, cancer, rheumatoid arthritis, and chronic age-dependent disease (2) . It has been reported that low levels of HDL-cholesterol (C) are associated with the incidence of cardiovascular disease and dementia (3) . Native apoA-I (nA-I) is a major constituent of HDL and exerts antioxidant and anti-inflammatory activity via removal of low-density lipoprotein (LDL) lipid hydroperoxide in vitro and in vivo when infused into mice and humans (4) . Serum apoA-I is a stronger prognostic marker than apo-B or the apo-B/apoA-I ratio and HDL-C or LDL-C for cardiovascular disease and mortality in elderly men (5) .
However, modification of apoA-I, such as nonenzymatic glycation, can lead to the production of dysfunctional apoA-I and HDL, which contributes to acceleration of degenerative disease and aging (6) . We recently reported that elevated levels of advanced glycated end (AGE) products in lipoproteins and fragmentation of apoA-I are present in the elderly, with decreased apoA-I levels and increased multimerized apoA-I in HDL (7) .
It has been suggested that reconstituted HDL (rHDL) containing apoA-I has a protective effect by neutralizing or detoxifying endotoxin (8) . However, the beneficial function of apoA-I can be hampered by oxidative stress, such as glycation, nitration, and chlorination. It has been proposed that glycation of apoA-I is a characteristic feature of senescence and chronic metabolic disease (7, 9, 10) . Glucosylated apolipoproteins are frequently present in the plasma of patients with diabetes who have impaired anti-inflammatory activity and increased susceptibility to infection (10) . Among carbohydrates, fructose is known to cause damage and aging in human tissues via fructation and fructosylation (9, 11) .
Other beneficial functions of HDL include antiaging activities as recently suggested by Walter (12) . HDL may modulate the aging process by interfering with an aging signaling factor. It has been proposed that HDL is involved in processes related to senescence (13) and dementia (14) as well as coronary artery disease. However, there is no direct evidence for an antiaging effect of apoA-I. In the current study, the putative antiaging activity of apoA-I and HDL was compared between the young and elderly using senescence-induced human dermal fibroblasts (HDFs). Furthermore, nA-I and glycated apoA-I (gA-I), in lipid-free and -bound states, were compared in cellular atherosclerotic events, such as modified LDL phagocytosis and cholesterol influx into macrophages.
Methods

Isolation of HDL From Elderly and Control Groups
Very low-density lipoprotein (d < 1.019 g/mL), LDL (1.019 < d < 1.063), HDL 2 (1.063 < d < 1.125), and HDL 3 (1.125 < d < 1.225) were isolated from the sera of elderly (mean age: 71 ± 4 years, n = 26) and young males (mean age: 22 ± 2 years, n = 18) via sequential ultracentrifugation, with the density being appropriately adjusted by the addition of NaCl and NaBr as detailed in our previous report (7) and in accordance with standard protocols (15) . Samples were centrifuged for 24 hours at 10°C at 100,000g using a Himac CP-90a (Hitachi, Tokyo, Japan) in the Instrumental Analysis Center at Yeungnam University.
Characterization of HDL and LDL
The protein concentrations of lipoproteins were determined via the Lowry protein assay as modified by Markwell and colleagues (16) , and the content of AGE products in the individual lipoproteins was determined from reading the fluorometric intensities at 370 nm (excitation) and 440 nm (emission) as described previously (17) using a spectrofluorometer (LS55; Perkin Elmer, Shelton, CT) with the WinLab software package (version 4.0). Phospholipid (PL) content was determined using a standard procedure (18) .
Purification of apoA-I and Its Glycation
ApoA-I was purified from human plasma using ultracentrifugation, column chromatography, and organic solvent extraction, following the method described by Brewer and colleagues (19) . The purified apoA-I was lyophilized at −80°C until use. Fructation of apoA-I to produce gA-I was carried out as recently described by our research group (9) .
DMPC Clearance Assay
Because apoA-I has potent PL-binding ability, the interactions of apoA-I with dimyristoyl phosphatidylcholine (DMPC) were monitored by the method described by Pownall and colleagues (20) with slight modifications. The mass ratio of DMPC-to-protein was 2:1 (wt/wt) in a 0.76 mL total reaction volume. The measurements were initiated after addition of DMPC and monitored at 325 nm every 2 minutes using a DU800 spectrophotometer (Beckman Coulter, Fullerton, CA) equipped with a MultiTemp III thermocirculator (AmershamBiosciences, Uppsala, Sweden).
Synthesis of rHDL
Reconstituted HDL containing nA-I or gA-I was prepared via sodium cholate dialysis at a molar ratio of 95:5:1:150 (palmitoyloleoyl phosphatidylcholine :cholesterol:apoA-I:sodium cholate) as previously described by our research group (21) . The relevant apolipoproteins and rHDLs were characterized in according to our previous report (22) . When necessary, fluorescent cholesterol derivatives (22-(N-7-nitrobenz-2-oxa-1,3-diazol-4-yl) amino-23,24-bisnor-5-cholen-3-ol [NBD-cholesterol], molecular probe N-1148, and 70 mg of NBD-cholesterol/mg of apoA-I) was added to the rHDL.
Purification of LDL, oxidation, and acetylation
LDL (1.019 < d < 1.063) was purified from human plasma (Blood Bank of Yeungnam University Medical Center, Daegu, Korea) from healthy male volunteers by ultracentrifugation according to a standard protocol (15) . Oxidized LDL was produced by incubating the LDL fraction with CuSO 4 (final concentration: 10 mM) for 4 hours at 37°C. The oxLDL was then filtered through a 0.22-mm filter (Millex; Millipore, Bedford, MA) and analyzed using a thiobarbituric acid-reacting substances assay to determine the extent of oxidation as described previously (23) .
The acetylation of LDL (acLDL) was performed using saturated sodium acetate and acetic anhydride according to the method previously described (24) . After acetylation and subsequent dialysis, the acLDL protein content was determined and filtered prior to use.
Antiatherosclerotic Assay
THP-1 cells, a human monocyte cell line, were obtained from the American Type Culture Collection (ATCC, #TIB-202; Manassas, VA, USA) and maintained in RPMI-1640 medium (Hyclone, Logan, UT) supplemented with 10% fetal bovine serum until needed. Cells that had undergone ≤20 passages were incubated in medium containing phorbol 12-myristate 13-acetate (final concentration: 150 nM) in 24-well plates for 48 hours at 37°C in a humidified incubator (5% CO 2 and 95% air) to induce differentiation into macrophages.
To compare antiatherosclerotic activity using a cellular model, E-HDL-and Y-HDL-induced inhibition was tested against LDL uptake by macrophages as previously reported by our research group (25) . The differentiated and adherent macrophages were then rinsed with warm phosphate-buffered saline (PBS) and incubated with 400 mL of fresh RPMI-1640 medium containing 1% fetal bovine serum, 50 mL of oxLDL (50 mg of protein in PBS) or acLDL (50 mg of protein in PBS), and 50 mL of each HDL (56 mg of protein [final concentration: 4 mM]) for 48 hours at 37°C in a humidified incubator. After incubation, the cells were stained with oil-red O solution (0.67%) to visualize the amount of lipid species in the cell. The cell media (0.2 mL) was then analyzed by the thiobarbituric acid-reacting substances assay to evaluate the changes in levels of oxidized species with a malondialdehyde (MDA) standard.
Antisenescence Assay
Primary HDF cells were cultured, and cellular senescenceassociated-b-gal activity was compared with the degree of senescence as described previously (26, 27) . For induction of senescence, cells at Passage 9 (approximately 40% confluence) were exposed to each HDL fraction (equally pooled from each group and diluted to a final protein concentration of 0.8 mM), lipid-free apoA-I (final concentration: 2 mM) in the native or glycated state, or fructose (final concentration: 5 mM) for the designated period.
To compare the extent of aging, cellular SA-b-gal activity was compared as previously described (26) . Cells were fixed for 5 minutes in 3% paraformaldehyde in PBS, washed three times in PBS, and incubated in SA-b-gal staining solution (40 mM citric acid/phosphate [pH: 6.0], 5 mM potassium ferrocyanide, 5 mM potassium ferricyanide, 150 mM NaCl, 2 mM MgCl 2 , and 1 mg/mL of 5-bromo-4-chloro-3-indolyl-X-galactosidase) for 16 hours at 37°C. The percentage of blue cells was calculated under light microscopic observation.
In addition, the level of expression of insulin-like growth factor-binding protein (IGFBP)-5 was compared in the cell lysate via Western blot analysis using antihuman IGFBP-5 antibody (AF875; R & D Systems, Minneapolis, MN) according to a previous report (28) . The same amount of protein (25 mg/lane) from each lysate was loaded after protein quantification using the Bradford reagent (Bio-Rad, Hercules, CA). The relative band intensity (BI) was compared via band scanning with a Gel Doc XR (Bio-Rad) using Quantity One software (version 4.5.2) after normalization to the BI of b-actin.
Cholesterol Influx Into Macrophages
To compare the cholesterol influx ability into macrophages, each HDL was labeled with NBD-cholesterol (molecular probe N-1148, 70 mg of NBD-cholesterol/mg of apoA-I). Each NBD-cholesterol-rHDL (containing gA-I or nA-I [final protein concentration, 2 mM]) and NBD-HDL 3 (equally pooled from the young and elderly [final protein concentration, 56 mg of protein/mL]) was treated into the differentiated THP-1 cells. After 48-hour treatment of each HDL or rHDL, the cells were thrice washed in PBS and the fluorescence (excitation = 488 nm, emission = 535 nm) in the cells as detected using the LS55 spectrofluorometer with WinLab software equipped with a Plate Reader (L2250140). The cell and fluorescence images were observed and photographed using a Nikon Eclipse TE2000 microscope (Tokyo, Japan). Quantification of fluorescence in the cell was carried out via computer-assisted morphometry using the Image Proplus software (version 4.5.1.22; Media Cybernetics, Bethesda, MD).
Statistical Analysis
All data are expressed as the mean ± SD from at least three independent experiments with duplicate samples. Comparisons between results were made by Student's t test using SPSS (version 12.0; SPSS, Inc., Chicago, IL). Statistical significance was defined as a p < .05.
Results
HDL From Elderly Was More Glycated With Less PL Content
Fluoroscopic observation revealed that E-HDL had a significantly greater extent of protein glycation as shown in Figure 1A . The elderly group had 2.3-and 2.9-fold more glycated products in the HDL 2 and HDL 3 fractions in an intact state, respectively, compared with the young group.
Determination of PL content revealed that E-HDL 3 and Y-HDL 3 had 0.9 ± 0.06 and 2.8 ± 0.06 mg of PL/mg of protein, respectively. This result suggests that E-HDL had a much decreased PL content (approximately 68% less content) in the same amount of apolipoproteins. 
ApoA-I Multimerization in E-HDL
The electrophoretic patterns of E-HDL 2 and E-HDL 3 had higher molecular weight bands (indicated by arrows in Figure 1B ) with slightly slower mobility and greater smear BI (lane E). Western blot analysis confirmed that the higher bands were multimerized bands of apoA-I (up to tetramers), and the band position of the apoA-I monomer was slightly shifted up in E-HDL ( Figure 1C ). These results suggest that apoA-I in E-HDL had altered properties by glycation.
E-HDL 3 Had More Proatherogenic Properties
As shown in Figure 2 , oxLDL-treated THP-1 cells had a much stronger red intensity than THP-1 cells not treated with oxLDL. E-HDL 3 -treated THP-1 cells had an increased extent of red intensity compared with Y-HDL 3 -treated THP-1 cells. Furthermore, Y-HDL 3 -treated cells had less production of oxidized species (3.7 nM of MDA) than E-HDL 3 -treated cells (4.6 nM of MDA). These results indicate that Y-HDL 3 had more antiatherosclerotic properties. However, there was no remarkable difference in red intensity between Y-HDL 2 -and E-HDL 2 -treated THP-1 cells, which had been treated with similar levels of oxidized species (4.2 nM of MDA). As a control and background, ox-LDL alone-and PBS alone-treated cells had 4.3 and 0.9 nM MDA, respectively. This result is in good agreement with a previous report that indicated HDL 3 was more specific for inhibition of early steps of foam cell formation (29) because phagocytosis of oxLDL is a key process of cellular atherosclerosis (30, 31) . However, the antiatherosclerotic activity of E-HDL 3 was diminished and even more so than E-HDL 2 , with an increase in oxidized species in the cell media (4.6 nM of MDA for E-HDL 3 treatment).
As shown in Figure 3 Determination of the oxidized species content revealed that E-HDL 3 -treated cells had more elevated MDA levels than Y-HDL 3 -treated cells in the presence or absence of acLDL. In the absence of acLDL, Y-HDL 3 -and E-HDL 3 -treated cells had 0.5 and 1.5 nM MDA, respectively. As a control and background, acLDL alone-and PBS alonetreated cells had 1.4 and 0.6 nM MDA, respectively. In the presence of acLDL, E-HDL 3 -treated cells had a 1.4-fold increase in the MDA level than Y-HDL 3 -treated cells as shown in Figure 3 . These results suggest that E-HDL 3 had more atherogenic and proinflammatory properties with or without acLDL in the cell media.
HDL From the Elderly Exacerbated Cellular Senescence
Treatment of HDFs with E-HDL resulted in more severe senescence as shown in 
Glycated apoA-I Showed Impaired PL-Binding Ability
After 90-hour incubation with fructose (final concentration: 5 mM) and apoA-I (2 mg/mL) under 5% CO 2 at 37°C, nonenzymatic glycation was produced as shown in Figure 5A . Glycated apoA-I showed more multimerized bands (up to tetramers) and smear BI with slight cleavage (28-kDa band; lane 2, Figure 5A ), which was a very similar pattern as apoA-I in E-HDL (Figure 1) , whereas nA-I showed a distinct band without multimerization.
To characterize the PL-binding affinity of nA-I and gA-I, the ability to lyse DMPC liposomes was examined at 24.5°C. As shown in Figure 5B , nA-I readily solubilized DMPC liposomes, whereas gA-I lost most of the binding affinity similar to tris-buffered saline. The half-life (T 1/2 ) of nA-I with respect to liposome clearance was approximately 44 ± 2 minutes, whereas gA-I did not reach 50% DMPC clearance during a 180-minute incubation.
Glycated apoA-I Induced Premature Cellular Senescence
There was no remarkable difference in the morphologic changes from Passages 9-18, regardless of the treatment group, except that the cell doubling time was attenuated and the cell density was lowered in the higher passage numbers (data not shown).
However, as shown in Figures 6 and 7A , the percentage of stained cells was remarkably increased in a passagedependent manner, especially in the gA-I-treated (final protein concentration: 2 mM) and fructose-treated cells (final fructose concentration: 5 mM). The percentage at Passage 18 was increased to 42%-45% in the gA-I-or fructosetreated cells. However, nA-I-treated cells had only 20% stained cells, which was similar to PBS-treated cells, indicating that gA-I treatment induced more premature cellular senescence unlike nA-I. As shown in Figure 6 , the SA-bgal-stained cells appeared as early as Passage 10 in the gA-I-or fructose-treated cells. Cotreatment of nA-I (final protein concentration: 2 mM) and fructose (final concentration: 5 mM) did not induce premature senescence, which was similar in extent to PBS treatment (Figures 6 and 7) , indicating that nA-I suppressed induction of senescence by fructose treatment. Western blotting with cell lysates (at Passage 13) showed that gA-I (lane 3) had a 16% increase in detection than nA-I (lane 5), suggesting that gA-I was more easily taken up into HDFs. Moreover, cotreatment of nA-I with fructose (lane 4) had an 87% increase in detection than nA-I alone (lane 5), indicating that glycation could facilitate cellular uptake of the modified apoA-I into HDFs via a putative receptor.
E-HDL 3 and gA-I-rHDL Facilitated Increased Cholesterol Influx Into Macrophages
After treatment of rHDL (28 mg of apoA-I) and HDL 3 (28 mg of protein) containing NBD-cholesterol, fluorescence was more readily detected in gA-I-rHDL-treated and E-HDL 3 -treated cells as shown in Figure 8A . Fluorescence Figure 8B ). This result suggests that E-HDL 3 and gA-IrHDL enhance cholesterol influx into macrophages, which accelerates growth of atherosclerotic plaques.
Discussion
Recently, the physiologic effects of fructose and AGE products have received attention because it contributes to the etiology of metabolic disorders and oxidative stress (32) . Dietary fructose is involved in metabolic syndrome and diabetes (33) ; however, a link between aging and fructose consumption has not been clearly established. Fructose Figure 6 . Induction of cellular senescence in human dermal fibroblasts treated with glycated apoA-I (gA-I). Cells were treated with lipid-free native apoA-I or lipid-free gA-I (final apoA-I concentration: 2 mM) for 40 days (from Passages 10-18), and SA-b-gal activity (stained as blue color) was measured as described in the "Methods" section. The cell image was captured using a Nikon Eclipse TE2000 microscope (Tokyo, Japan) at 400× magnification. is involved in the production of reactive oxygen species, an increase in serum triglycerides in humans (34) , and increased uric acid synthesis in a mouse model (35) .
In the current report, we showed that E-HDL 2 and E-HDL 3 were more glycated and apoA-I was modified (Figure 1 ) similar to gA-I ( Figure 5A, lane 2) . Y-HDL 2 and Y-HDL 3 showed nearly no multimeric bands and increased distinct BI, which was similar to nA-I ( Figure 5A, lane 1) . E-HDL 3 was degenerated to be a proatherosclerotic (Figures 2 and 3 ) and prosenescent molecule (Figure 4 ) similar to gA-I ( Figure 6 ) and gA-I-rHDL (Figure 8 ). Treatment with E-HDL caused more uptake of oxLDL and acLDL into macrophages (Figures 2 and 3 ) and cellular senescence (Figure 4) . Glycation of apoA-I led to dysfunctional HDL, the gA-I lost PL-binding ability ( Figure 5B ), and the gA-I accelerated cellular senescence to a similar extent as fructose treatment alone (Figures 6 and 7A) . Western blot analysis revealed increased detection of gA-I than nA-I in cell lysates. Interestingly, cotreatment of nA-I and fructose in cell culture medium stimulated increased uptake of apoA-I than nA-I treatment alone (Figures 6 and 7) . These results suggest that AGE production is increased at physiologic conditions in which apoA-I and fructose are exposed to 5% CO 2 at 37°C. Similarly, increased AGE can accelerate cellular cholesterol influx from gA-I-rHDL and E-HDL into macrophages, as shown in Figure 8 , suggesting that increased gA-I may facilitate uptake of cholesterol into macrophages via a putative AGE receptor, such as CD-36 and scavenger receptor class B-type I as previously reported (36) . The increased influx of cholesterol into macrophages might contribute to the growth of fatty streak lesions in blood vessels.
Interestingly, gA-I induced the greatest extent of cellular senescence similar to fructose treatment (Figures 6 and 7) . SA-b-gal-positive cells appeared as early as Passage 10 because the experiments commenced on Passage 9. SA-bgal-positive cells appeared as early as Passage 10 because the experiments commenced on Passage 9, indicating that cellular senescence was caused by dysfunctional apoA-I. Another interesting finding of this study was that the cellular senescence was suppressed by lipid-free nA-I treatment (Figures 6 and 7) . There have been no reports directly demonstrating the antiaging effect of lipid-free apoA-I. However, in the current report, nA-I-treated cells showed a reduced number of SA-b-gal-positive cells than PBStreated cells, strongly suggesting that nA-I has an antiaging effect in the HDF.
The reason why E-HDL 3 had less PL content than Y-HDL 3 can be explained, at least in part, by the loss of DMPC-binding ability in gA-I ( Figure 5B ) because E-HDL 3 was more glycated ( Figure 1A) . Increased glycation might lead to impairment of PL binding, and less lipid binding might result in production of smaller HDL particles as in our recent report (7) . We recently showed that E-HDL 3 (n = 22) had a smaller width and length than Y-HDL 3 (8.4-11.7 nm), whereas C-HDL 3 (n = 18) had a width and length of 11.8-15.3 nm.
The loss of PL-binding ability ( Figure 5B ) is in good agreement with a previous report by Calvo and colleagues (37) . They reported that glucosylated apoA-I, which was purified from the plasma of patients with type 2 diabetes, had slower DMPC clearance activity. Similarly, an apoA-I variant that lacks Lys107 had decreased lipid-binding affinity (38) , indicating that Lys is important in PL-binding activity. The loss of PL-binding ability might be connected to production of smaller rHDL particles with a more heterogeneous band population and less apoA-I molecules (9) . These results indicate that in vivo glycation of lipid-free apoA-I may interfere with normal formation of nascent HDL (preb-HDL) and interrupt the efflux of cholesterol from the cell membrane because the amphipathic domain, which is crucial for lipid binding, is severely modified. It has been known that several domains of apoA-I, including the C-terminal domain, are important to lipid-binding ability and formation of HDL (39) .
Oxidized LDL is known for cytotoxicity as a potent inflammatory molecule in atherosclerosis-related vascular and coronary events (40, 41) . Oxidized LDL-treated cells had a reduced cell number compared with acLDL-treated cells, suggesting that oxLDL was much more cytotoxic than acLDL. E-HDL 3 did not inhibit acLDL phagocytosis into macrophages. Increased uptake efficiency of E-HDL 3 into THP-1 cells ( Figure 3B ) was well correlated with the results of increased cholesterol influx by E-HDL 3 as shown in Figure 8 . Furthermore, Y-HDL 3 was more effective in preventing cellular senescence in HDFs (Figure 4) . These results strongly suggest that HDL 3 possesses stronger antiinflammatory and antiaging activities than HDL 2 . Although it has been proposed that HDL 3 exerts more potent antioxidant and anti-inflammatory abilities than HDL 2 (42) , this is the first report to provide evidence in support of the antiaging activity of HDL 3 . However, the antiatherosclerotic and antiaging effects of HDL 3 could be decreased more so than HDL 2 via modification of apoA-I and glycation as shown in Figures 2 and 4 , respectively.
In conclusion, Y-HDL 3 was less glycated and more effective in preventing cellular senescence than E-HDL 3 .
Glycated apoA-I was multimerized and lost PL-binding ability and caused more cellular senescence than native apoA-I. Glycated apoA-I-rHDL and E-HDL lost antiatherosclerotic and antioxidant activities and showed enhanced cellular influx of cholesterol. However, nA-I exerted a beneficial effect, including anti-inflammation and antiaging activity in macrophages and HDF cells. Native apoA-I appears to mediate the antiatherogenic and antiaging effects of HDL. These results suggest that fructose-mediated glycation of apoA-I and HDL is a critical process to form dysfunctional HDL in the circulation, which has proinflammatory, pro atherogenic, and proaging properties.
